Skip to main content

Table 1 Baseline characteristics

From: Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery

Variable Perioperative Transfusion: Yes (N=51)
Mean (SD)
Perioperative Transfusion: No (N=15)
Mean (SD)
P-value
Age 69.0 (11.46) 71.1 (9.60) 0.5278
BMI 28.0 (7.31) 26.7 (5.68) 0.5183
Histology:
 High grade pap serous 46 14 0.299
 Low grade 2 0  
 Mucinous 1 0  
 Clear cell 2 0  
 Endometrioid 0 1  
 Pre-treatment CA125 3013.4 (5833.6) 2156.9 (2897.4) 0.5863
 Pre-operative CA125 198.8 (401.6) 462.8 (1585.2) 0.2822
Normal Pre-op:
 Yes 11 9 0.005
 No 39 6  
 Delta CA125 2867.5 (5702.6) 1694.2 (1592.9) 0.4361
Pre-op Clinical Stage:
 Stage 3 36 11 0.992
 Stage 4 13 4  
Pre-op Chemo:    0.907
 Carboplatin/Paclitaxel 41 13  
 Carbo/taxol/bevacizumab 5 1  
 Other 4 1  
Dose-dense Taxol:    0.258
 Yes 4 0  
 No 46 15  
Pre-op Chemotherapy cycle #    0.21
 3 or less 37 8  
 < 3 14 7  
Optimal Cytoreduction:    0.812
 No visible 12 (23.5%) 5 (33.3%)  
 1-5mm 9 (17.6%) 3 (20%)  
 ≤1cm 22 (43.1%) 6 (40%)  
 Suboptimal 7 (13.7%) 1 (6.7%)  
Final Stage:    0.646
 Ic 1   
 IIIc 38 10  
 IVa 8 4  
 IVb 4 1  
 Pre-op HgB (g/dL) 10.5 (0.16) 11.5 (0.44) 0.0091
 Operative blood loss (mL) 613.7 (421 ) 283.3 (144.7 ) 0.004
Number of Units Transfused    
 zero units 0 15  
 1-3 units 36 0  
 4-7 units 15 0  
 Days to death 662.9 (65.7) 865.8 (177.6) 0.1959
Alive:    0.918
 Yes 14 4  
 No 35 10  
  1. Median time to death was compared between patients who received perioperative blood transfusion (red line) versus those who did not (blue line). OS = 23.6 months for transfusion group; OS = 22.5 months for no transfusion group. Data were analyzed using the log-rank test